Barclays
ARKG icon

Barclays’s ARK Genomic Revolution ETF ARKG Stock Holding History

Barclays’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-27,400
Closed -$1.15M – 5392
2026
Q2 		$1.15M Buy
+27,400
New +$873K ﹤0.01% 2708
2025
Q4 		– Sell
-15
Closed -$417 – 5228
2025
Q3 		$417 Sell
15
-15,586
-100% -$394K ﹤0.01% 5214
2025
Q2 		$380K Sell
15,601
-20,774
-57% -$455K ﹤0.01% 3911
2025
Q1 		$755K Buy
36,375
+14,375
+65% +$361K ﹤0.01% 3272
2024
Q4 		$518K Sell
22,000
-263,108
-92% -$6.48M ﹤0.01% 3801
2024
Q3 		$7.3M Buy
285,108
+204,283
+253% +$5.2M ﹤0.01% 1732
2024
Q2 		$1.9M Sell
80,825
-60,410
-43% -$1.52M ﹤0.01% 2189
2024
Q1 		$4.06M Buy
141,235
+133,341
+1,689% +$4.01M ﹤0.01% 2006
2023
Q4 		$259K Sell
7,894
-44,226
-85% -$1.2M ﹤0.01% 4302
2023
Q3 		$1.45M Buy
52,120
+51,060
+4,817% +$1.67M ﹤0.01% 2088
2023
Q2 		$36.1K Hold
1,060
– – ﹤0.01% 3967
2023
Q1 		$31.9K Sell
1,060
-1,389
-57% -$43K ﹤0.01% 4554
2022
Q4 		$69.1K Sell
2,449
-8,896
-78% -$282K ﹤0.01% 4424
2022
Q3 		$373K Sell
11,345
-47,060
-81% -$1.73M ﹤0.01% 2861
2022
Q2 		$1.84M Buy
58,405
+8,800
+18% +$308K ﹤0.01% 1906
2022
Q1 		$2.28M Buy
49,605
+2,454
+5% +$117K ﹤0.01% 1770
2021
Q4 		$2.89M Buy
47,151
+37,410
+384% +$2.59M ﹤0.01% 2122
2021
Q3 		$728K Buy
9,741
+210
+2% +$17.6K ﹤0.01% 2976
2021
Q2 		$882K Sell
9,531
-560
-6% -$47.6K ﹤0.01% 2737
2021
Q1 		$896K Buy
10,091
+1,560
+18% +$155K ﹤0.01% 2841
2020
Q4 		$796K Buy
+8,531
New +$680K ﹤0.01% 2921

Other funds holding ARKG

Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Florin Court Capital
Florin Court Capital London, United Kingdom $97M AUM 40.08% 1-Year Est. Return
NTV Asset Management
NTV Asset Management Charleston, West Virginia $1.08B AUM 23.94% 1-Year Est. Return
Midwest Financial Partners Investments
Midwest Financial Partners Investments St. Cloud, Minnesota $260M AUM 10.89% 1-Year Est. Return
Canal Insurance Company
Canal Insurance Company Greenville, South Carolina $426M AUM 30.47% 1-Year Est. Return
Gimbal Financial
Gimbal Financial Carmel, Indiana $172M AUM
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return
Riggs Asset Management
Riggs Asset Management Dallas, Pennsylvania $541M AUM 40.97% 1-Year Est. Return

Barclays's ARKG Position: Q3 2026 in Review

Barclays sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2026, closing a stake of 27,400 shares — an estimated $1.15M sold.

Barclays first reported a position in ARKG in Q4 2020 and held it in 21 quarters. The position peaked at $7.3M in Q3 2024. 166 funds tracked by Wall St. Rank hold ARKG as of Q3 2026.

  • Barclays reported no remaining ARK Genomic Revolution ETF position as of Q3 2026 after selling out during the quarter.
  • Barclays sold 27,400 ARK Genomic Revolution ETF shares in Q3 2026, an estimated $1.15M.
  • Barclays first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 21 quarters.
  • Barclays's ARK Genomic Revolution ETF position peaked at $7.3M in Q3 2024.
  • 166 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.